Atorvastatin Reduces Plasma Inflammatory and Oxidant Biomarkers in Patients With Risk of Atherosclerotic Cardiovascular Disease
| Autor: | Fadia Mayyas, Rasheed K. Ibdah, Duha Baydoun, Khalid S. Ibrahim |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Atorvastatin Inflammation 030204 cardiovascular system & hematology medicine.disease_cause Gastroenterology Coronary artery disease Superoxide dismutase 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine medicine Humans Pharmacology (medical) Prospective Studies Aged Peroxidase Pharmacology Dose-Response Relationship Drug Endothelin-1 biology Superoxide Dismutase business.industry C-reactive protein Middle Aged Atherosclerosis Oxidants medicine.disease Lipids Endothelin 1 Oxidative Stress C-Reactive Protein 030104 developmental biology Myeloperoxidase biology.protein Female Hydroxymethylglutaryl-CoA Reductase Inhibitors medicine.symptom Cardiology and Cardiovascular Medicine business Oxidative stress medicine.drug |
| Zdroj: | Journal of Cardiovascular Pharmacology and Therapeutics. 23:216-225 |
| ISSN: | 1940-4034 1074-2484 |
| DOI: | 10.1177/1074248417753677 |
| Popis: | Oxidative stress and inflammation are associated with endothelial injury and coronary artery disease. Inflammatory factors that promote oxidative damage include endothelin-1 (ET-1), myeloperoxidase (MPO), and C-reactive protein (CRP). Current guidelines recommend the use of statins in patients with risk of atherosclerotic cardiovascular disease (ASCVD).To assess the impact of atorvastatin on plasma inflammatory and oxidant biomarkers in patients with moderate to very high risk of ASCVD.Two hundred ten patients presented to the cardiology clinic were included and stratified into low, moderate, high, and very high risk of ASCVD. Moderate- (20 mg/d) to high-intensity (40 mg/d) atorvastatin was prescribed. Plasma levels of lipids, ET-1, CRP, MPO, total nitrite, lipid peroxides (thiobarbituric acid reactive substances [TBARS]), and superoxide dismutase (SOD) activities were measured at baseline and 12 weeks after treatment.Relative to low-risk patients, baseline plasma inflammatory markers of CRP, MPO, ET-1, and nitrite were higher in patients with very high risk of ASCVD, whereas plasma SOD was lower (all P.05). Use of high and moderate atorvastatin therapy significantly reduced low-density lipoprotein and total cholesterol levels, as well as plasma levels of CRP, MPO, nitrite, and TBARS, and increased plasma SOD activity in patients with moderate to very high risk of ASCVD, independent of lipid-lowering effects.Key markers of oxidative stress/inflammation such as CRP, ET-1, total nitrite, and MPO are associated with an increased risk of ASCVD. Moderate- and high-intensity atorvastatin use reduces plasma oxidative stress and inflammation regardless of ASCVD risk and independent of its lipid-lowering effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|